FDA Panel Endorses Capivasertib Use in Prostate Cancer

(MedPage Today) — FDA’s independent advisors on Thursday endorsed the use of capivasertib (Truqap) for treating an aggressive subtype of prostate cancer.
By a 7-1 vote, and with a single abstention, the Oncologic Drugs Advisory Committee agreed…